Your Health. Your Family. Your Choice.
|History of Changes from the VAERS Wayback Machine|
|Vaccination / Manufacturer||Lot / Dose||Site / Route|
|COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH||- / 2||LA / -|
Administered by: Public Purchased by: ??
Symptoms: Postmenopausal haemorrhage
Life Threatening? No
Birth Defect? No
Permanent Disability? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Preexisting Conditions: Medical History/Concurrent Conditions: COVID-19; Postmenopause
Diagnostic Lab Data:
CDC 'Split Type': USPFIZER INC2021515479
Write-up: I am post menopausal, I am bleeding and have period like symptoms; This is a spontaneous report from a contactable consumer (patient). A 52-year-old non-pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number was not reported), at 52 years old via an unspecified route of administration, administered in Arm Left on 28Apr2021 10:30 as 2nd dose, single for COVID-19 immunization in a public health department. Medical history included diagnosed with COVID-19 and post menopausal both from an unknown date. Concomitant medications include an unspecified medication taken within two weeks of vaccination. The patient received the first dose of bnt162b2 on 07Apr2021 11:00 AM for COVID-19 immunization. On 04May2021 08:30, the patient reported that she is post menopausal, was bleeding and have period like symptoms. The reporter considered the event as non-serious. No treatment was given. The outcome of the event was unknown. Information on the lot/batch number has been requested.
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166